MOH (Oman)

The Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC) within Oman’s Ministry of Health is the statutory authority for medicines (including biologics and vaccines), medical devices and IVDs, cosmetics, dietary supplements, pharmacy practice, and controlled substances. Its remit is grounded in the Health Law (Royal Decree 41/1996), the Pharmacy Profession and Establishments Law (Royal Decree 35/2015), and the Narcotics and Psychotropic Substances Law (Royal Decree 17/1999). In practice, DGPA&DC registers products and manufacturers, licenses importers and wholesalers, oversees pharmacy licensing, and inspects for cGMP, GDP for pharma, and good pharmacy practice. It also supervises advertising, pricing, and post‑market surveillance, with official information channels available through the Ministry’s site at moh.gov.om and legal texts accessible on qanoon.om.

Oman is a largely import‑dependent market where most dossiers are foreign‑origin and must appoint an Omani‑resident Authorized Representative to manage regulatory correspondence and vigilance. Arabic and English labeling is mandatory, and the submitted artwork must faithfully mirror the approved reference text. DGPA&DC may check supply‑chain readiness as part of market entry; authorities expect storage and distribution controls to be commensurate with local climatic realities. Sponsors that map their regulatory and quality threads to an integrated pharmacovigilance system and a documented stability program generally experience smoother national steps after scientific review.

Public procurement is concentrated through the Oman Tender Board’s eProcurement system (etendering.tenderboard.gov.om). Pricing submissions are assessed against national rules and regional comparators; documentation of ex‑factory prices and reference markets is often requested. DGPA&DC collaborates with Ministry supply and laboratory functions for sampling and surveillance, which can include import testing or market checks. Sponsors should keep registration files synchronized with controlled documents, using systems that lock Arabic–English artwork under change control and preserve a clear audit trail, such as Document Control within a broader QMS and Periodic Document Review processes.

As a GCC Member State, Oman uses regional harmonization and reliance on stringent regulatory authority outcomes where appropriate. Abridged routes will typically consider approvals from EMA, MHRA, FDA (fda.gov), Swissmedic (swissmedic.ch), and MFDS (mfds.go.kr), among others, provided the submitted dossier matches the approved content. DGPA&DC also participates in the WHO Prequalification ecosystem, leveraging collaborative procedures where applicable; see WHO Prequalification and the WHO regulation hub (https://www.who.int/teams/regulation-prequalification) for context.

DGPA&DC expects manufacturing to conform to internationally recognized GMP standards. For finished dosage forms, EU/WHO GMP principles are the baseline; for APIs, ICH Q7 is the critical reference. Oman is not a PIC/S member, but it relies on inspection outcomes and GMP certificates from authorities that participate in or align with PIC/S standards (see https://picscheme.org/). In practice, manufacturers provide recent GMP certificates and inspection evidence from stringent regulators, along with a Pharmaceutical Quality System mapped to ICH Q10 and risk management per ICH Q9. Where sterile operations are concerned, alignment with EU GMP Annex 1 for sterile products is expected.

Oman’s climate—hot interiors and humid coasts—drives stability and transport controls. Sponsors should justify shelf life with ICH Q1A‑consistent data and zone IV expectations, using container‑closure systems that mitigate moisture and heat. The national laboratory may verify claims through sampling; therefore, analytical method validation and reference standards should be unambiguous and traceable. A defensible stability program that anticipates temperature excursions, lane validation for summer months, and controlled distribution documents under GDP for pharma are routinely examined during assessment and inspection.

Lifecycle control matters. Omani reviewers frequently look for evidence of change control, deviation/CAPA, and annual product quality reviews integrated into the PQS. Cleanroom classifications, sterilization validations, and aseptic behaviors for sterile products must be consistent with the firm’s global quality system and current guidance. Data integrity expectations extend across manufacturing, QC, and batch records; tools that support paperless validation and auditable documentation help resolve questions quickly. For local start‑ups in Sohar, Salalah, or Duqm, gap‑assessing against WHO GMP (see WHO GMP TRS 1044, 2022) and EU GMP Parts I/II is a prudent first step.

For planning, consult practical primers such as ICH Q7 API GMP readiness, ICH Q10 Pharmaceutical Quality System readiness, and regional overviews like GCC Pharmaceutical GMP Readiness. These resources help assemble validation maps, cleaning studies, and quality agreements while organizing evidence under controlled documentation via Document Control and cross‑functional reviews via Management Review.

DGPA&DC operates multiple registration routes that blend national scientific assessment with reliance on stringent authority decisions and WHO procedures. Choice of pathway depends on product type, prior approvals, public‑health priority, and dossier fidelity to the reference approval. Early coordination of pricing with the Tender Board can save time on the critical path, particularly for public‑sector launches. Quality elements should echo ICH Q1A, ICH Q7, ICH Q10, and a risk‑managed lifecycle per ICH Q9, while the labeling must be bilingual and harmonized with the core SmPC/PI.

For new chemical entities and novel biologics without prior approval by a stringent regulator, a full national review applies. If a product is authorized by EMA, MHRA, FDA (https://www.fda.gov/), Health Canada, TGA, Swissmedic (https://www.swissmedic.ch/swissmedic/en/home.html), or MFDS (https://www.mfds.go.kr/eng/index.do), DGPA&DC can apply an abridged reliance approach provided the submitted CTD matches the approved content. WHO‑prequalified vaccines and selected medicines may access collaborative procedures under WHO Prequalification, facilitating information exchange to compress timelines while preserving national decisions on labeling, pharmacovigilance, and import controls.

Generics and biosimilars emphasize equivalence and quality. Expect zone IV data consistent with ICH stability and, where appropriate, bioequivalence or biosimilarity packages that align with WHO and ICH principles. Variations are categorized by risk and impact on quality, safety, or efficacy, with documentary evidence expected under controlled change management. Sponsors preparing regional launches can leverage harmonized technical positions described in GCC Pharmaceutical GMP Readiness, ensuring that stability, serialization, and Arabic artwork converge early.

Reliance is central to Omani regulatory strategy. For products evaluated by a stringent body—EMA, MHRA, FDA (https://www.fda.gov/), Swissmedic (https://www.swissmedic.ch/swissmedic/en/home.html), MFDS (https://www.mfds.go.kr/eng/index.do), and peers—the abridged pathway allows DGPA&DC to focus on local conditions while leveraging prior assessments. Success depends on dossier identity: formulation, manufacturing sites, batch sizes, control strategy, and labeling must match the reference approval, with any deltas justified via controlled variations. Maintaining clean, version‑controlled documents through Document Control and capturing the change history within a QMS is invaluable.

WHO collaborative mechanisms can further shorten timelines for eligible products. Under WHO Prequalification, assessment and inspection outcomes are shared with participating national authorities, expediting local decisions. Even then, sponsors must provide validated cold‑chain and transport data compatible with Oman’s climate, and align Arabic–English labeling with the core reference. For scientific context on reliance and international work‑sharing, the EMA’s international activities page (https://www.ema.europa.eu/en/partners-networks/international-activities) provides a useful benchmark for global practices.

Regional coordination across the Gulf can be efficient for portfolio launches, but it also amplifies the need for early harmonization. Arabic artwork, serialization choices, and distributor networks should be planned across Oman and peers such as Saudi SFDA, UAE MoHAP, Kuwait MoH, and Bahrain NHRA. A consistent approach to storage statements and shelf life—anchored to ICH Q1A and zone IV expectations—reduces the risk of divergent national demands that can complicate tenders.

When Omani‑specific factors matter (for example, Arabic HCP materials, device usability in primary‑care settings, heat‑exposure during desert transport, or differences in hospital workflows), DGPA&DC may probe further even in reliance routes. Sponsors that pre‑empt these questions, structure evidence to ICH/WHO norms, and document distributor training and complaint handling can typically avoid late‑stage clock stops. Organizing reliance dossiers and national adaptations with traceable controls through Document Control and governance via Management Review helps sustain alignment.

DGPA&DC regulates medical devices and IVDs through a risk‑based framework aligned with IMDRF/GHTF principles, applying reliance on authorization in stringent jurisdictions where appropriate. For higher‑risk classes, prior approval or conformity evidence from the EU/UK, United States, Canada, Australia, Switzerland, or South Korea is often the practical precondition to an abridged Omani process. Technical files should include clinical or performance evaluation evidence, PMS plans, and quality‑system certification, and they must preserve traceability to configurations and identifiers such as UDI and UDI‑DI vs UDI‑PI.

Foreign manufacturers must appoint an Omani‑resident Authorized Representative or importer who is responsible for vigilance, complaint handling, and field safety corrective actions. Arabic and English labeling, including IFUs and warnings, is mandatory. For IVDs used in public programs, cold‑chain design and transport validation should reflect Omani summer peaks. Sponsors launching across the Gulf benefit from harmonized technical positions that anticipate differences among Saudi SFDA, UAE MoHAP, Kuwait MoH, and Bahrain NHRA, using planning playbooks such as GCC Medical Device Regulatory Readiness.

Cosmetics and personal‑care goods are subject to notification or registration depending on claims and risk; therapeutic claims will redirect products to the medicines or devices framework. Dietary supplements undergo composition and specification checks, ingredient safety substantiation, and bilingual labeling review that must avoid disease claims and misleading statements. Post‑market sampling by the Ministry’s laboratories can verify quality and labeling compliance; therefore, the technical file should align methods with pharmacopeial or recognized standards and ensure test reproducibility.

For hospital tenders, ensure that model configurations, options, and Arabic artwork match what is being bid. PMS and post‑market surveillance plans should reflect local training commitments and spare‑parts availability. Technical traceability (e.g., UDI) and a clear association between serial/lot ranges and Arabic FSNs help hospitals act quickly during recalls. For manufacturers managing diverse product families, organizing technical evidence and bilingual IFUs with eBMR/eDHR and shareable documentation supports consistent submissions and faster procurement responses.

Oman participates in the WHO Programme for International Drug Monitoring and contributes to VigiBase through its National Pharmacovigilance Centre. Marketing authorization holders must maintain a local pharmacovigilance system and a designated Omani contact, reconciling safety data from distributors, literature, and health‑care providers. Case handling should align with ICH formats where applicable, and periodic reports are expected consistently with global standards. Reference material on pharmacovigilance is maintained by WHO (https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance) and UMC (https://www.who-umc.org/). See also Pharmacovigilance for system design concepts.

For vaccines, AEFI reporting via national immunization channels must be integrated into the MAH’s signal detection and risk‑minimization plan. Quality complaints with potential safety consequences should be captured and analyzed within the PV system, triggering corrective and preventive actions. For combination products or temperature‑sensitive medicines, trend analysis on transport deviations can be as important as clinical case narratives; link these streams back to the stability program and GDP controls to ensure that risk evaluations are data‑complete.

Matériovigilance for medical devices and IVDs requires timely reporting of serious incidents, near‑misses with potential for serious harm, and field safety corrective actions. Field Safety Notices should be prepared in Arabic and English, with traceability to affected batches, serial ranges, or UDI values. Where incidents span several Gulf markets, DGPA&DC expects harmonized corrective actions and synchronized timelines, with Omani‑specific user communications and retrieval logistics planned. The structure and cadence of PMS should be aligned with reliance jurisdictions while remaining workable within local health‑care workflows.

Strong post‑market systems reduce procurement risk and build clinical confidence. Hospitals increasingly ask for complaint handling metrics, uptime commitments, and training plans during tender evaluations. MAHs can streamline compliance by integrating PV and device PMS with controlled documentation and by cross‑referencing reliance dossiers maintained under Document Control. For organizations operating in WHO PQ contexts, align your risk plans with expectations summarized under WHO Prequalification so that safety communications and labeling stay synchronized across markets.

Most setbacks in Oman arise not from missing CTD sections but from mismatches between dossier claims and Omani realities. A recurring example is stability: long‑term data at 25°C is submitted to justify 36‑month shelf life, but real lanes exceed 40–45°C in summer. DGPA&DC will challenge such claims, reduce shelf life, or mandate restrictive storage statements, which can compromise tenders. Anchor your arguments to ICH Q1A and zone IV expectations such as ICH Stability Zone IVb, and verify packaging suitability with transport validation.

Another frequent delay is artwork. Arabic translations delivered late, or diverging from the approved SmPC/PI, can trigger multiple iterations. In reliance filings, quiet changes to sites, batch sizes, or analytical methods versus the reference approval convert an abridged review into a variation sequence. Use controlled documentation—e.g., Document Control—and governance via Management Review to keep labeling, CPPs, GMP certificates, and pricing dossiers synchronized. For devices, gaps in Arabic IFUs, UDI mapping, or service plans often surface only when hospitals perform technical evaluations.

Commercial documentation can also become a bottleneck. Price files that ignore GCC reference rules invite resubmission. Missing or expired legalized CPP/Free Sale or GMP certificates delay acceptance. Post‑approval, incomplete importer authorizations, unclear QPPV delegation, or missing PV system files create findings during surveillance visits. Sponsors who pre‑stage experimental plans and validation traces—using references like IQ/OQ/PQ Process Validation Readiness—avoid rework when DGPA&DC asks for confirmatory evidence or lane studies.

• Submit zone IV long‑term stability supporting claimed shelf life; validate summer transport lanes above 40°C.
• Lock Arabic–English labeling to the approved reference; preserve a traceable artwork history.
• Match reliance dossiers exactly to the reference approval or file controlled variations with data.
• Prepare pricing files aligned to regional reference rules with documented ex‑factory/public prices.
• Legalize CPP/Free Sale and GMP certificates with validity that covers the review window.
• Designate an Omani Authorized Representative and local PV contact; file PV system documents early.
• For devices/IVDs, provide Arabic IFUs, UDI/lot mapping, and service plans aligned to tender SKUs.

Bringing products to Oman requires synchronized control of reliance documentation, Arabic–English labeling, GMP/GDP evidence, and post‑market data. V5 Ultimate centralizes these elements and their relationships so teams can answer DGPA&DC queries with primary evidence on demand. Registration baselines tie back to validated manufacturing and QC records; stability claims connect to distribution controls and labeling; and auditable histories are preserved for pre‑ and post‑approval inspections. This reduces last‑minute document hunts and aligns regulatory narratives to what operations can actually prove.

Core quality processes are captured in one system: Document Control locks reference‑aligned dossiers and bilingual artwork; QMS provides governed change control and training visibility; Lab QC manages zone IV studies, container‑closure verification, and lane validations; and QC Release supports import testing and sampling holds. Device teams can link design, manufacturing, and servicing evidence with eBMR/eDHR, ensuring that technical files and Arabic IFUs remain consistent across variants and tender SKUs.

Externally sourced certificates, CPPs, and Authorized Representative attestations are coordinated via the Supplier Portal, while regulatory tasks and pricing dossiers remain visible to cross‑functional leads. Observations from DGPA&DC inspections or market checks are routed to owners with Audits and CAPA Auto‑routing, and progress is summarized with Management Review dashboards. Where regional alignment is essential, controlled copies for Gulf peers—Saudi SFDA, UAE MoHAP, Kuwait MoH, and Bahrain NHRA—can be managed from a single governed source.